MRK Stock Analysis — Merck & Co.
Sector: Healthcare
AI Verdict
Merck trades at 21.9x next year's earnings while analysts expect a -29.9% drop in EPS—you're paying a full price for a shrinking bottom line, so unless the drug pipeline delivers a surprise, the numbers don't justify optimism.
Competitive Moat
Merck's defensibility comes from its deep pipeline of patented drugs, especially in oncology and vaccines, which create high barriers to entry due to regulatory approval and R&D scale. Its Keytruda franchise benefits from entrenched clinical data and ongoing label expansions that competitors struggle to match.
Summary
Merck’s Keytruda cancer drug remains a blockbuster, but the stock is under scrutiny as earnings expectations contract sharply.
Where It Stands
MRK is up 35.24% over the past year, trades at 21.9x forward earnings versus a healthcare sector median of 22x, and its RSI of 36.1 signals shares are near oversold territory.
Key Metrics
- RSI: 36.1 — Near Oversold
- Trailing P/E: 15.4x
- Forward P/E: 21.9x
- Earnings Growth: -0.3%
- Revenue Growth: +0.0%
- Market Cap: $276.4B
- 1-Year Return: 35.24%
Bull Case
A trailing P/E of 15.4x is well below the sector median, suggesting the market is still giving some credit for Merck’s drug pipeline and historical profitability.
Bear Case
With forward EPS expected to drop -29.9% and a forward P/E of 21.9x, any further multiple compression to the sector median would erase much of the recent 35.24% gain.
Catalyst to Watch
Watch for clinical trial results or FDA decisions on pipeline drugs—positive outcomes could offset the projected earnings decline.